Protalix wins EU panel backing for expanded dosing of Fabry disease drug
Protalix BioTherapeuticsProtalix BioTherapeutics(US:PLX) Proactiveinvestors NA·2026-01-30 15:20

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across multiple sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Protalix BioTherapeutics-Protalix wins EU panel backing for expanded dosing of Fabry disease drug - Reportify